RAGE Inhibition to Decrease Cancer Related Cognitive Decline (CRCD) in Women With Non-metastatic Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2023-11-01

Summary

This is a pilot study to evaluate the safety and tolerability of azeliragon when administered with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Georgetown University
• Treatments: Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Liposomal doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab